Xeris Biopharma Q4 Earnings Call Highlights

2 weeks ago 9

MarketBeat

Mon, March 2, 2026 astatine 9:37 AM CST 7 min read

Xeris Biopharma logo

Financial milestone: Xeris reported 2025 gross up 44% to $291.8 million, delivered astir $60 cardinal of adjusted EBITDA and achieved its archetypal full-year nett income, calling the twelvemonth a measurement to financial self-sustainability.
2026 guidance and pipeline push: The institution guided to $375–$390 cardinal successful gross (more than 30% maturation astatine the midpoint) and expects to stay adjusted EBITDA affirmative portion expanding R&D (~+$25M) and SG&A (~+$45M) and initiating Phase III for XP-8121 successful H2 2026.
Recorlev is the maturation engine: Recorlev much than doubled to $139.3 cardinal successful 2025 with ~700 patients, the commercialized squad was astir doubled for expansion, and Xeris has filed patent suits to support the franchise (Orange Book patents to 2040; orphan exclusivity done 2028).
Interested successful Xeris Biopharma Holdings, Inc.? Here are 5 stocks we similar better.

Xeris Biopharma (NASDAQ:XERS) reported crisp top-line maturation successful the 4th fourth and afloat twelvemonth 2025, highlighted by what absorption described arsenic a “defining milestone” for the company: fiscal self-sustainability. On its 4th fourth net call, executives besides outlined a 2026 outlook calling for much than 30% gross maturation astatine the midpoint, alongside accrued concern successful some the company’s pb maturation brand, Recorlev, and its pipeline programme XP-8121.

Chief Executive Officer John Shannon said 2025 was a “transformational year,” pointing not lone to gross maturation but besides to profitability and the company’s quality to self-fund its strategy. Total gross grew 43% year-over-year successful the 4th fourth to $85.8 million, and roseate 44% for the afloat twelvemonth to $291.8 million.

→ The Head Fake: Buying the Chinese Stocks Post-Ruling Dip

Chief Financial Officer Steve Pieper said show reflected “continued underlying request crossed our portfolio,” and noted that the institution delivered astir $60 cardinal of adjusted EBITDA for the year. Xeris besides reported nett income successful the 4th fourth and, arsenic a result, nett income connected a full-year ground for 2025.

Management emphasized broad-based request crossed Xeris’s 3 commercialized products, with Recorlev driving the largest stock of growth.

Recorlev: Fourth 4th gross was $45.3 cardinal and full-year gross was $139.3 million, representing maturation of much than 100% successful some periods, according to the CFO. Shannon said the diligent basal expanded to astir 700 patients by year-end 2025, astir doubling from year-end 2024. He attributed maturation to expanding prescriber consciousness and expanding assurance successful Recorlev’s objective profile.
Gvoke: Fourth 4th gross was $24.6 cardinal and full-year gross was $94.1 million. Shannon said Gvoke posted 14% maturation for the year, supported by wide entree and alignment with attraction guidelines. Pieper added that 2025 results benefited from favorable gross-to-net dynamics.
Keveyis: Fourth 4th gross was $12.8 cardinal and full-year gross was $47.6 million. Management said Keveyis continued to outperform expectations, supported by an summation successful the mean fig of patients connected therapy, and noted the relation of diligent enactment for radical surviving with superior periodic paralysis.